drugset / Trial / NCT01028209

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209

Phase 1 Terminated 12 enrolled Institute for Neurodegenerative Disorders
NaSingle-groupOpen-labelDiagnostic

Summary

The underlying goal of this study is to assess \[18F\] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.

Timeline

Start
2009-11
Primary completion
2010-09-22
Completion
2010-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject [F-18]PBR06 Diagnostic / imaging agent 185 mbq